Nyxoah has secured $110 million in new capital to support the U.S. commercial expansion of its Genio implantable therapy for obstructive sleep apnea (OSA).
The financing includes $95 million in equity funding and an expected $15 million second tranche from the European Investment Bank loan. The funds will support the company’s next phase of U.S.-focused growth.
Related: Nanordica Medical raises €1.6M to advance antibiotic-free wound care technology
Nyxoah plans to accelerate adoption of Genio in the U.S., where it has already established a commercial team of 40 sales representatives. The device is designed to provide an innovative treatment option for OSA patients.
CEO Olivier Taelman said:
“This is a defining moment for Nyxoah… this capital will allow Nyxoah to accelerate the commercial ramp of Genio in the United States and deliver on its mission for OSA patients.”
Board Chairman Robert Taub added:
“The strong participation of both new and existing investors is a powerful endorsement of our Genio technology, our strategy and our team.”
The funding strengthens Nyxoah’s ability to expand Genio’s U.S. presence and advance its position in the sleep apnea treatment market.
